{"filing":{"accession_number":"0001193125-26-346796","cik":"0001001233","ticker":"SGMO","company_name":"SANGAMO THERAPEUTICS, INC","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-06","primary_document":"d21956d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1001233/000119312526346796/d21956d8k.htm"},"events":[{"id":27145,"run_id":24721,"accession_number":"0001193125-26-346796","anchor_item_number":"7.01","event_type":"bankruptcy_filing","event_domain":"terminal","is_material":true,"confidence":0.99,"summary":"Sangamo Therapeutics filed a voluntary Chapter 11 petition on June 23, 2026 (Case No. 26-10989), and this 8-K Item 7.01 discloses the filing of its monthly operating report for the bankruptcy case. The disclosure explicitly states the company \"filed a voluntary petition for relief under Chapter 11 of Title 11 of the United States Code\" and notes the company's stock has been delisted from Nasdaq and is trading on the OTC market under \"SGMOQ.\" This is a terminal event materially threatening the registrant's continued existence.","company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28547,"accession_number":"0001193125-26-346796","item_number":"7.01","item_title":null,"event_type":"bankruptcy_filing","event_domain":"terminal","is_material":true,"confidence":0.99,"reasoning":"Sangamo Therapeutics filed a voluntary Chapter 11 petition on June 23, 2026 (Case No. 26-10989), and this 8-K Item 7.01 discloses the filing of its monthly operating report for the bankruptcy case. The disclosure explicitly states the company \"filed a voluntary petition for relief under Chapter 11 of Title 11 of the United States Code\" and notes the company's stock has been delisted from Nasdaq and is trading on the OTC market under \"SGMOQ.\" This is a terminal event materially threatening the registrant's continued existence.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:05:17.283413+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28547,"accession_number":"0001193125-26-346796","item_number":"7.01","item_title":null,"event_type":"bankruptcy_filing","event_domain":"terminal","is_material":true,"confidence":0.99,"reasoning":"Sangamo Therapeutics filed a voluntary Chapter 11 petition on June 23, 2026 (Case No. 26-10989), and this 8-K Item 7.01 discloses the filing of its monthly operating report for the bankruptcy case. The disclosure explicitly states the company \"filed a voluntary petition for relief under Chapter 11 of Title 11 of the United States Code\" and notes the company's stock has been delisted from Nasdaq and is trading on the OTC market under \"SGMOQ.\" This is a terminal event materially threatening the registrant's continued existence.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:05:17.283413+00:00","company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","filing_date":"2026-08-12"}]}